Overview

Evaluating HA 0.15% Compared With Cyclosporine 0.05%, and Efficacy of Combination Therapy in Dry Eye Disease Patients

Status:
Unknown status

Trial end date:
2020-12-01

Target enrollment:

Participant gender:

Summary

In patients with moderate to severe dry eye syndrome, the test drug (HA 0.15% eye drop) or the control drug (cyclosporin 0.05% eye drop) is administered for 12 weeks, and the corneal staining of each group would be evaluated. The study objective is to demonstrate that the test drug is not clinically inferior to the control drug. Furthermore, the efficacy of combination therapy would be evaluated through exploratory combination therapy group.

Phase:

Phase 4

Details

Lead Sponsor:

Taejoon Pharmaceutical Co., Ltd.

Treatments:

Cyclosporine
Cyclosporins